期刊
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
卷 1865, 期 2, 页码 255-265出版社
ELSEVIER
DOI: 10.1016/j.bbcan.2016.03.005
关键词
Cytokine; Cancer drug resistance; Stromal cells; Tumor microenvironment; Antibody array; Multiplex immunoassay
资金
- Guangdong innovative research team program [201001s0104659419]
- Foundation of Enterprise University Research Institute Cooperation of Guangdong Province and Ministry of Education of China [2012B090600021, 2012B091000145]
- Special program for the development of technology business incubators in Guangzhou [2013J4200016]
- National High Technology Research and Development Program 863 [2014AA020905]
- 'Five-twelfth' National Science and Technology Support Program [2012EP001000]
- UK-China (Guangzhou) Healthtech Open Innovation [2014Q-P037]
- Guangdong Provincial Science and Technology SME Technology Innovation Fund Program [2015A010101492]
- Innovative Research Fund
The development of oncoprotein-targeted anticancer drugs is an invaluable weapon in the war against cancer. However, cancers do not give up without a fight. They may develop multiple mechanisms of drug resistance, including apoptosis inhibition, drug expulsion, and increased proliferation that reduce the effectiveness of the drug. The collective work of researchers has highlighted the role of cytokines in the mechanisms of cancer drug resistance, as well as in cancer cell progression. Furthermore, recent studies have described how specific cytokines secreted by cancer stromal cells confer resistance to chemotherapeutic treatments. In order to gain a better understanding of mechanism of cancer drug resistance and a prediction of treatment outcome, it is imperative that correlations are established between global cytokine profiles and cancer drug resistance. Here we discuss the recent discoveries in this field of research and discuss their implications for the future development of effective anti-cancer medicines. (C) 2016 The Authors. Published by Elsevier B.V.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据